Associated Papers
Molecular insights for the tumor suppressor role of SPOP in prostate cancer.
Yan P et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2026
Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.
Wang R et al.
Cancer Research Communications, 2025
The equilibrium between two quaternary assembly states determines the activity of SPOP and its cancer mutants.
Cuneo MJ et al.
Biorxiv : the Preprint Server for Biology, 2025
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence.
Arce-Gallego S et al.
Cell Reports. Medicine, 2025
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.
Wang R et al.
Cancer Research Communications, 2023
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
Cavalcante L et al.
Jco Precision Oncology, 2023
Mass spectrometry-based targeted proteomics for analysis of protein mutations.
Lin TT et al.
Mass Spectrometry Reviews, 2023
Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA et al.
Cancer Research Communications, 2022
Detection of disease-causing mutations in prostate cancer by NGS sequencing.
Mangolini A et al.
Cell Biology International, 2022
Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L et al.
Cancer Research, 2021
Somatic Evolution in Non-neoplastic IBD-Affected Colon.
Olafsson S et al.
Cell, 2020
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo J et al.
The Journal of Clinical Investigation, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q et al.
Molecular Cancer, 2019
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y et al.
Embo Molecular Medicine, 2019
SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2018
Identification of SPOP related metabolic pathways in prostate cancer.
Yan M et al.
Oncotarget, 2017
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Wang H et al.
Journal of Translational Medicine, 2017
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
Jin X et al.
Plos Genetics, 2017
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.
Kim E et al.
Cancer Discovery, 2016
Genetic Progression of High Grade Prostatic Intraepithelial Neoplasia to Prostate Cancer.
Jung SH et al.
European Urology, 2016